About: ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.59 (-4.79%)
PROK NASDAQ ProKidney Corp.
ProKidney Corp. share price
PROK price activity
Last Price
$1.590
Change (24hr)
-0.08 USD (-4.79%)
Volume
1.31M
Volume (4w avg)
-
Open
$1.65
Day Range
$1.59 - $1.65
Previous Close
$1.67
Last Trade
13 Oct, 6:32 pm GMT+0
Delayed
13 Oct, 6:32 pm GMT+0
PROK price performance
Delayed
13 Oct, 6:32 pm GMT+0
PROK Market Signals